• Monte Rosa Therapeutics Inc GLUE.OQ reported a quarterly adjusted loss of 56 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of 23 cents. The mean expectation of seven analysts for the quarter was for a loss of 35 cents per share. Wall Street expected results to range from -52 cents to -2 cents per share.

• Revenue fell 95.4% to $2.78 million from a year ago; analysts expected $15.51 million.

• Monte Rosa Therapeutics Inc's reported EPS for the quarter was a loss of 56 cents​.

• The company reported a quarterly loss of $46.14 million.

• Monte Rosa Therapeutics Inc shares had risen by 2.2% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 6% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Monte Rosa Therapeutics Inc is $30.50, about 47.4% above its last closing price of $16.03

This summary was machine generated from LSEG data March 18 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)